Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Focus Universal Inc. Announces Participation at The Spartan Capital Investor Conference
-
Super League Gaming (SLE) PT Lowered to $3 at Maxim Group
-
Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
-
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
-
B2i Digital Named Marketing Partner for Maxim Group's 2024 Healthcare Virtual Summit
-
Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit
-
Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024
-
Jet.AI (JTAI) Prices 26.6M Share Offering at $0.09/sh
-
Jet.AI Announces Pricing of $2.4 Million Registered Direct Offering
-
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
-
Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
-
Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit
-
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
-
BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events
-
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
-
Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
-
Myomo to Participate in the 2024 Maxim Healthcare Virtual Summit
-
Inhibikase Therapeutics (IKT) Prices $110M Private Placement to Advance IkT-001Pro
-
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
-
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
-
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
-
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
-
SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit
-
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
-
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
-
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
-
Autonomix Medical, Inc. to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
-
Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit
-
Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
-
Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
-
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit
-
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit
-
Moleculin to Present at Two Upcoming Investor Conferences
-
Maxim Group Reiterates Buy Rating on Worksport Ltd. (WKSP)
-
Moolec Science SA (MLEC) PT Lowered to $3 at Maxim Group
-
Gain Therapeutics to Participate at Upcoming Investor Conferences
-
Genenta Science (GNTA) Secures Approval for Trial for Metastatic Renal Cell Cancer
-
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
-
ZenaTech Inc., AI Drone and Enterprise SaaS Company, Announces Direct Listing on the Nasdaq Capital Market Under the Symbol ZENA
-
NeuroBo Pharmaceuticals to Participate in Investor Conferences in October
-
ZenaTech Inc., AI Drone and Enterprise SaaS Company, Announces Direct Listing on the Nasdaq Capital Market Under the Symbol ZENA
-
ZenaTech Inc., AI Drone and Enterprise SaaS Company, Announces Direct Listing on the Nasdaq Capital Market Under the Symbol ZENA
-
Edible Garden Announces Closing of $5.65 Million Public Offering
-
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
-
ZenaTech Announces Approval to List Common Shares on the Nasdaq Capital Market
-
ZenaTech Announces Approval to List Common Shares on the Nasdaq Capital Market
-
ZenaTech Announces Approval to List Common Shares on the Nasdaq Capital Market
-
Ryde Announces Closing of $4.5 Million Public Offering
-
Edible Garden AG (EDBL) Prices 15.7M Share Offering at $0.36/sh
-
Edible Garden Announces Pricing of $5.65 Million Public Offering

